BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND CDX2, CDX3, 1045, ENSG00000165556, Q99626 AND Prognosis
105 results:

  • 1. ZEB1 hypermethylation is associated with better prognosis in patients with colon cancer.
    Fernandez-De-Los-Reyes I; Gomez-Dorronsoro M; Monreal-Santesteban I; Fernandez-Fernandez A; Fraga M; Azcue P; Alonso L; Fernandez-Marlasca B; Suarez J; Cordoba-Iturriagagoitia A; Guerrero-Setas D
    Clin Epigenetics; 2023 Dec; 15(1):193. PubMed ID: 38093305
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Multivariate Prognostic Models for Patients with Stages I and Ii Colon Carcinoma: a Strobe-Compliant Retrospective Cohort Study.
    Oñate-Ocaña LF; Herrera-Goepfert R; Avilés-Salas A; Cortés CC; González-Trejo S; Carrillo JF; Ruiz-García E; Ochoa-Carrillo FJ; Aiello-Crocifoglio V; García-Cuellar CM
    Rev Invest Clin; 2023; 75(5):259-271. PubMed ID: 37918013
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The prognostic potential of cdx2 in colorectal cancer: Harmonizing biology and clinical practice.
    Badia-Ramentol J; Gimeno-Valiente F; Duréndez E; Martínez-Ciarpaglini C; Linares J; Iglesias M; Cervantes A; Calon A; Tarazona N
    Cancer Treat Rev; 2023 Dec; 121():102643. PubMed ID: 37871463
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Loss of SATB2 and cdx2 expression is associated with DNA mismatch repair protein deficiency and BRAF mutation in colorectal cancer.
    Li J; Zeng Q; Lin J; Huang H; Chen L
    Med Mol Morphol; 2024 Mar; 57(1):1-10. PubMed ID: 37583001
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. cdx2 Is a Prognostic Biomarker for Unresectable Metastatic colorectal cancer.
    Mukohyama J; Agawa K; Yamashita K; Matsuda T; Shinoda M; Itano O; Kakeji Y
    Anticancer Res; 2023 Aug; 43(8):3763-3767. PubMed ID: 37500172
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Deciphering Brain Metastasis Stem Cell Properties From colorectal cancer Highlights Specific Stemness Signature and Shared Molecular Features.
    Desette A; Guichet PO; Emambux S; Masliantsev K; Cortes U; Ndiaye B; Milin S; George S; Faigner M; Tisserand J; Gaillard A; Brot S; Wager M; Tougeron D; Karayan-Tapon L
    Cell Mol Gastroenterol Hepatol; 2023; 16(5):757-782. PubMed ID: 37482243
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Pattern of expression of cdx2 in colorectal cancer and its role in prognosis.
    Singh J; Rajesh NG; Dubashi B; Maroju NK; Ganesan P; Matta KK; Charles I; Kayal S
    J Cancer Res Ther; 2022 Dec; 18(Supplement):S420-S427. PubMed ID: 36510997
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Immunohistochemical analysis of the distribution of RANKL: a case of disseminated carcinomatosis of bone marrow as the first presentation of relapse in curatively resected colorectal cancer.
    Shimada Y; Nagaba Y; Okawa H; Ehara K; Okada S; Naito M; Yokomori H
    Med Mol Morphol; 2023 Jun; 56(2):138-143. PubMed ID: 36478259
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. cdx2 as a Predictive Biomarker Involved in Immunotherapy Response Suppresses Metastasis through EMT in colorectal cancer.
    Wang YS; Kou Y; Zhu RT; Han BW; Li CH; Wang HJ; Wu HB; Xia TM; Che XM
    Dis Markers; 2022; 2022():9025668. PubMed ID: 36277982
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer.
    Mochizuki K; Kudo SE; Kato K; Kudo K; Ogawa Y; Kouyama Y; Takashina Y; Ichimasa K; Tobo T; Toshima T; Hisamatsu Y; Yonemura Y; Masuda T; Miyachi H; Ishida F; Nemoto T; Mimori K
    PLoS One; 2022; 17(10):e0273566. PubMed ID: 36264865
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Combination of cdx2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.
    Derangère V; Lecuelle J; Lepage C; Aoulad-Ben Salem O; Allatessem BM; Ilie A; Bouché O; Phelip JM; Baconnier M; Pezet D; Sebbagh V; Terrebonne E; Bouard G; Jooste V; Bouvier AM; Molimard C; Monnien F; Gonzalez D; Le Malicot K; Rageot D; Truntzer C; Bibeau F; Ghiringhelli F;
    Eur J Cancer; 2022 Sep; 172():221-230. PubMed ID: 35785606
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. The Complete Loss of p53 Expression Uniquely Predicts Worse prognosis in colorectal cancer.
    Nagao K; Koshino A; Sugimura-Nagata A; Nagano A; Komura M; Ueki A; Ebi M; Ogasawara N; Tsuzuki T; Kasai K; Takahashi S; Kasugai K; Inaguma S
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328677
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Current Perspectives on the Importance of Pathological Features in Prognostication and Guidance of Adjuvant Chemotherapy in Colon cancer.
    Chen K; Wang H; Collins G; Hollands E; Law IYJ; Toh JWT
    Curr Oncol; 2022 Feb; 29(3):1370-1389. PubMed ID: 35323316
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. cdx2 controls genes involved in the metabolism of 5-fluorouracil and is associated with reduced efficacy of chemotherapy in colorectal cancer.
    Delhorme JB; Bersuder E; Terciolo C; Vlami O; Chenard MP; Martin E; Rohr S; Brigand C; Duluc I; Freund JN; Gross I
    Biomed Pharmacother; 2022 Mar; 147():112630. PubMed ID: 35051860
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. [A Case of Multiple Hepatic Metastases after Surgery for Low Differentiated Mucous cancer of Sigmoid Colon with Notable Mesenteric Infiltration in Which Chemotherapy Was Effective].
    Tani H; Takaishi H; Ihara T; Murakami D; Aratake K
    Gan To Kagaku Ryoho; 2021 Dec; 48(13):2155-2157. PubMed ID: 35045523
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Pathological Features and Prognostication in colorectal cancer.
    Chen K; Collins G; Wang H; Toh JWT
    Curr Oncol; 2021 Dec; 28(6):5356-5383. PubMed ID: 34940086
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, cdx2 and BRAF status: a population-based study of metastatic colorectal cancer patients.
    Aasebø K; Bruun J; Bergsland CH; Nunes L; Eide GE; Pfeiffer P; Dahl O; Glimelius B; Lothe RA; Sorbye H
    Br J Cancer; 2022 Jan; 126(1):48-56. PubMed ID: 34671130
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Loss of CDX-2 expression is an independent poor prognostic biomarker in patients with early-stage deficient mismatch repair colorectal cancer.
    Korphaisarn K; Sukhokanjanachusak K; Pongpaibul A; Chinswangwatanakul V; Akewanlop C
    Asia Pac J Clin Oncol; 2022 Jun; 18(3):249-258. PubMed ID: 34161647
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Outcomes and Prognostic Factors of Patients with Metastatic colorectal cancer Who Underwent Pulmonary Metastasectomy with Curative Intent: A Brazilian Experience.
    Gössling GCL; Chedid MF; Pereira FS; da Silva RK; Andrade LB; Peruzzo N; Saueressig MG; Schwartsmann G; Parikh AR
    Oncologist; 2021 Sep; 26(9):e1581-e1588. PubMed ID: 33896091
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Prognostic significance of MUC2, cdx2 and SOX2 in stage II colorectal cancer patients.
    Ribeirinho-Soares S; Pádua D; Amaral AL; Valentini E; Azevedo D; Marques C; Barros R; Macedo F; Mesquita P; Almeida R
    BMC Cancer; 2021 Apr; 21(1):359. PubMed ID: 33823840
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 6.